The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 randomized cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mCPRC): Results for 2nd-line therapy.
 
Daniel Khalaf
No Relationships to Disclose
 
Matti Annala
No Relationships to Disclose
 
Daygen L. Finch
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; Novartis; Pfizer
Speakers' Bureau - Pfizer
 
Conrad D. Oja
No Relationships to Disclose
 
Joanna Vergidis
Honoraria - Astellas Pharma; Bayer; Janssen; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Pfizer
Travel, Accommodations, Expenses - Astellas Pharma; Bayer
 
Muhammad Zulfiqar
No Relationships to Disclose
 
Katherine Sunderland
No Relationships to Disclose
 
Kevin Beja
No Relationships to Disclose
 
Gillian Rae Vandekerkhove
No Relationships to Disclose
 
Martin Gleave
Stock and Other Ownership Interests - OncoGenex
Honoraria - Abbvie; Astellas Pharma; Bayer; Janssen; Oncogenex; Sanofi
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Janssen; Oncogenex; Sanofi
Research Funding - Astellas Pharma; Bayer; Janssen
Patents, Royalties, Other Intellectual Property - OncoGenex - OGX-011, OGX-427
 
Alexander William Wyatt
Consulting or Advisory Role - Genzyme
Speakers' Bureau - Janssen
 
Kim N. Chi
Honoraria - Amgen; Astellas Pharma; Janssen; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; ESSA; Janssen; Lilly/ImClone; Sanofi
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Lilly/ImClone (Inst); Novartis (Inst); Oncogenex (Inst); Sanofi (Inst); Teva (Inst); Tokai Pharmaceuticals (Inst)